Mrd

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio.

Edit

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

Pharmiweb 05 Feb 2026

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncology portfolio.

Edit

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market (Form 8-K) (BioNexus Gene Lab Corp)

Public Technologies 03 Feb 2026

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market ... Residual Disease (MRD) platform.

Edit

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant ...

The Joplin Globe 02 Feb 2026

PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)--Feb 2, 2026-- ... .

Edit

Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

PR Newswire 02 Feb 2026

Called Quest Flow Cytometry MRD for Myeloma, the new test provides ... Quest is a leading provider of oncology testing services, including the Haystack MRD® test for assessing MRD in solid tumor cancers.

Edit

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ...

Nasdaq Globe Newswire 28 Jan 2026

... today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform.

Edit

Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer (Chugai Pharmaceutical Co Ltd)

Public Technologies 28 Jan 2026

Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer ... therapeutic option for high-risk, MRD-positive muscle-invasive bladder cancer.

Edit

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Nasdaq Globe Newswire 27 Jan 2026

Myriad advances Precise MRD toward a March 2026 launch, backed by new breast and colorectal cancer data showing ultrasensitive ctDNA detection ... .

Edit

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

The Galveston Daily News 21 Jan 2026

AUSTIN, Texas--(BUSINESS WIRE)--Jan 21, 2026-- ....

Edit

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

Business Wire 13 Jan 2026

... (MRD)-based risk stratification that is expected to extend the company’s leadership in oncology.

Edit

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Business Wire 13 Jan 2026

Clinicians using the NeXT Personal MRD test will now be able to opt-in for additional reporting ...

Podcasts:

Latest News for: mrd

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and ...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, ...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD,

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials ...

Invivoscribe��Launches LeukoStrat��KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient ...

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market (Form 8-K) (BioNexus Gene Lab Corp)

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant ...

Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ...

Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer (Chugai Pharmaceutical Co Ltd)

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Article Search

EXPLORE WN.com